Project Grant R01HL179577
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $714K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $734,986 on August 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genetic architecture research on natriuretic peptides and their role in blood pressure regulation. The research leverages whole genome sequencing data from multiethnic cohorts—including the Transomics for Precision Medicine cohorts, UK Biobank, and All of Us Research Program—to identify common,...
- The National Heart, Lung, and Blood Institute awarded the University of Oklahoma Health Sciences Center $638,245 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hypothalamic melanocortin 4 receptor (MC4R) signaling pathways in sympathetic regulation of blood pressure, with particular focus on obesity-induced hypertension mechanisms. The research examines how MC4R signaling in hypothalamic neurons regulates sympathetic outflow and blood...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,491,464 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, for Project Grant R01HL178770, a research study comparing ambulatory blood pressure monitoring (ABPM) to wrist-worn home blood pressure monitoring (HBPM) in assessing end-organ damage. The study, titled AW-COMPARE, will evaluate whether wrist-worn HBPM devices can replace ABPM as the reference standard for...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 21, 2025, with a completion date of June 30, 2027. The grant supports the development of a clinical decision support questionnaire designed to identify barriers to blood pressure control among adults with hypertension. This tool addresses a critical gap in...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $774,398 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate circadian clock regulation of stress pathways in heart failure with preserved ejection fraction. The research examines how circadian disruption—misalignment between external circadian cues and internal molecular clocks, occurring in 15–30% of the population due to shift work and social jet lag—contributes...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $881,454 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish relationships between poor access to healthy food, inadequate clinical care, and hypertension progression in youth, and to identify strategies to overcome these barriers. The award supports research under the Study of the Epidemiology of Pediatric Hypertension (SUPERHERO) Registry, a longitudinal...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $754,413 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized controlled trial of remote blood pressure monitoring, pharmacist-led telehealth medication management, and automated text reminders integrated into an emergency department transitional care clinic model for hypertensive patients. The trial, titled REMAP-BP (Remote Blood Pressure...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $874,014 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the relationship between gut microbiota, metabolite composition, and salt sensitivity of blood pressure. The research quantifies salt sensitivity of blood pressure as the change in 24-hour ambulatory mean arterial pressure from one week of high-salt to one week of low-salt diet in 50 adult subjects...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $223,438 on September 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a clinical research study examining hypertension incidence in people with HIV initiating antiretroviral therapy (ART). The project, scheduled for completion by August 31, 2027, will assess blood pressure outcomes in ART-naïve individuals starting either...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...